159 related articles for article (PubMed ID: 7567690)
1. Quantitative evaluation of glandular and stromal compartments in hyperplastic dog prostates: effect of 5-alpha reductase inhibitors.
Laroque PA; Prahalada S; Molon-Noblot S; Cohen SM; Soper K; Duprat P; Peter CP; van Zwieten MJ
Prostate; 1995 Sep; 27(3):121-8. PubMed ID: 7567690
[TBL] [Abstract][Full Text] [Related]
2. Effects of chronic oral administration of a selective 5 alpha-reductase inhibitor, finasteride, on the dog prostate.
Laroque PA; Prahalada S; Gordon LR; Noblot SM; Bagdon WJ; Duprat P; Peter CP; Van Zwieten MJ
Prostate; 1994; 24(2):93-100. PubMed ID: 8309848
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the effects of new specific azasteroid inhibitors of steroid 5 alpha-reductase on canine hyperplastic prostate: suppression of prostatic DHT correlated with prostate regression.
Cohen SM; Werrmann JG; Rasmusson GH; Tanaka WK; Malatesta PF; Prahalada S; Jacobs JG; Harris G; Nett TM
Prostate; 1995 Feb; 26(2):55-71. PubMed ID: 7531846
[TBL] [Abstract][Full Text] [Related]
4. Qualitative and quantitative evaluation of prostatic histomorphology in rats following chronic treatment with finasteride, a 5-alpha reductase inhibitor.
Prahalada SR; Keenan KP; Hertzog PR; Gordon LR; Peter CP; Soper KA; van Zwieten MJ; Bokelman DL
Urology; 1994 May; 43(5):680-5. PubMed ID: 7513109
[TBL] [Abstract][Full Text] [Related]
5. 5 alpha-reductase activity in cultured epithelial and stromal cells from normal and hyperplastic human prostates--effect of finasteride (Proscar), a 5 alpha-reductase inhibitor.
Boudon C; Lobaccaro JM; Lumbroso S; Lechevallier E; Mottet N; Gibelin B; Sultan C
Cell Mol Biol (Noisy-le-grand); 1995 Dec; 41(8):1007-15. PubMed ID: 8747081
[TBL] [Abstract][Full Text] [Related]
6. Evidence for atrophy and apoptosis in the prostates of men given finasteride.
Rittmaster RS; Norman RW; Thomas LN; Rowden G
J Clin Endocrinol Metab; 1996 Feb; 81(2):814-9. PubMed ID: 8636309
[TBL] [Abstract][Full Text] [Related]
7. 5 alpha-reductase inhibition by finasteride (Proscar) in epithelium and stroma of human benign prostatic hyperplasia.
Weisser H; Tunn S; Debus M; Krieg M
Steroids; 1994 Nov; 59(11):616-20. PubMed ID: 7535480
[TBL] [Abstract][Full Text] [Related]
8. Atrophic effects of antiandrogen, chlormadinone acetate (CMA) on dog prostate with spontaneous benign prostatic hyperplasia.
Murakoshi M; Tagawa M; Ikeda R
J Toxicol Sci; 2000 Aug; 25(3):143-50. PubMed ID: 10987120
[TBL] [Abstract][Full Text] [Related]
9. Effect of finasteride (Proscar) on the proliferation of cultured epithelial and stromal cells from normal and hyperplastic human prostates.
Lobaccaro JM; Boudon C; Lechevallier E; Mottet N; Rebillard X; Lumbroso S; Gibelin B; Sultan C
Cell Mol Biol (Noisy-le-grand); 1996 Jun; 42(4):511-8. PubMed ID: 8828906
[TBL] [Abstract][Full Text] [Related]
10. 5alpha-reductase activity in the prostate.
Steers WD
Urology; 2001 Dec; 58(6 Suppl 1):17-24; discussion 24. PubMed ID: 11750244
[TBL] [Abstract][Full Text] [Related]
11. Long-term inhibition of 5-alpha reductase and aromatase changes the cellular and extracellular compartments in gerbil ventral prostate at different postnatal ages.
Corradi LS; Campos SG; Santos FC; Vilamaior PS; Góes RM; Taboga SR
Int J Exp Pathol; 2009 Feb; 90(1):79-94. PubMed ID: 19200255
[TBL] [Abstract][Full Text] [Related]
12. Expression of basic fibroblast growth factor and its receptors FGFR1 and FGFR2 in human benign prostatic hyperplasia treated with finasteride.
Sáez C; González-Baena AC; Japón MA; Giráldez J; Segura DI; Rodríguez-Vallejo JM; González-Esteban J; Miranda G; Torrubia F
Prostate; 1999 Jul; 40(2):83-8. PubMed ID: 10386468
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological and molecular evidence for the expression of the two steroid 5 alpha-reductase isozymes in normal and hyperplastic human prostatic cells in culture.
Berthaut I; Mestayer C; Portois MC; Cussenot O; Mowszowicz I
Prostate; 1997 Aug; 32(3):155-63. PubMed ID: 9254894
[TBL] [Abstract][Full Text] [Related]
14. Treatment of benign prostatic hyperplasia with 5-alpha-reductase inhibitor: morphological changes in patients who fail to respond.
Montironi R; Valli M; Fabris G
J Clin Pathol; 1996 Apr; 49(4):324-8. PubMed ID: 8655710
[TBL] [Abstract][Full Text] [Related]
15. 5alpha-reductase inhibitors: what role should they play?
Kaplan SA
Urology; 2001 Dec; 58(6 Suppl 1):65-70; discussion 70. PubMed ID: 11750255
[TBL] [Abstract][Full Text] [Related]
16. Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled, multicenter study. PROWESS Study Group.
Marberger MJ
Urology; 1998 May; 51(5):677-86. PubMed ID: 9610579
[TBL] [Abstract][Full Text] [Related]
17. Regressive changes in finasteride-treated human hyperplastic prostates correlate with an upregulation of TGF-beta receptor expression.
Sáez C; González-Baena AC; Japón MA; Giráldez J; Segura DI; Miranda G; Rodríguez-Vallejo JM; González-Esteban J; Torrubia F
Prostate; 1998 Oct; 37(2):84-90. PubMed ID: 9759702
[TBL] [Abstract][Full Text] [Related]
18. The corpus cavernosum after treatment with dutasteride or finasteride: A histomorphometric study in a benign prostatic hyperplasia rodent model.
Da Silva MHA; Costa WS; B Sampaio FJ; De Souza DB
Asian J Androl; 2018; 20(5):505-510. PubMed ID: 29893293
[TBL] [Abstract][Full Text] [Related]
19. CGP 53153: a new potent inhibitor of 5alpha-reductase.
Häusler A; Allegrini PR; Biollaz M; Batzl C; Scheidegger E; Bhatnagar AS
J Steroid Biochem Mol Biol; 1996 Feb; 57(3-4):187-95. PubMed ID: 8645628
[TBL] [Abstract][Full Text] [Related]
20. Effect of combination treatment with zanoterone (WIN 49596), a steroidal androgen receptor antagonist, and finasteride (MK-906), a steroidal 5 alpha-reductase inhibitor, on the prostate and testes of beagle dogs.
Juniewicz PE; Hoekstra SJ; Lemp BM; Barbolt TA; Devin JA; Gauthier E; Frenette G; Dube JY; Tremblay RR
Endocrinology; 1993 Aug; 133(2):904-13. PubMed ID: 8393778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
